• Immix Biopharma investor presentation highlighted NXC-201, a BCMA-targeted CAR-T being developed for relapsed or refractory AL amyloidosis, a setting it estimates at about 38,500 U.S. patients with no FDA-approved drugs.
• Clinical data referenced from ASH 2025 showed a 75% complete response rate for NXC-201, versus 0-10% complete response cited for current investigator’s-choice regimens in relapsed or refractory disease.
• Company outlined a registrational design for U.S. NEXICART-2, with final readout targeted for topline in Q3, followed by a planned BLA submission.
• Commercial timeline calls for launch planning in late 2026, with a commercial launch plan in 1H 2027.
• Presentation also framed NXC-201 as a platform candidate beyond AL amyloidosis, targeting plasma cells across selected immune-mediated diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.